Phase II study with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and genecitabine (GEM) in metastatic pancreas cancer

Wein, Axel; Wehler, Markus; Fischer, Bernhard; Boxberger, Frank; Lampert, S.; Riedel, Christian U.; Kastl, S.; Hohenberger, Werner; Hahn, Eckart G.; Schneider, Thomas

doi:10.1016/s0016-5085(08)83046-6

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gemcitabine has subsequently been studied in a large number of randomised phase III studies. These studies involving alternative comparisons including both 5‐FU and novel therapies have reinforced its activity and reconfirmed the initial data 53−58 …”

Section: Metastatic Diseasementioning

confidence: 70%

“…Attempts to improve upon this with other agents that are either synergistic in laboratory studies or other tumours have been mixed. Neither cisplatin, 5‐FU, even in the most active schedules such as infusional or with leucovorin, capecitabine, or irinotecan have increased survival 53−59 . Most recently, adding oxaliplatin has shown superior progression‐free survival but full survival data is still awaited 60 .…”

Section: Metastatic Diseasementioning

confidence: 99%

See 1 more Smart Citation

Modern management of pancreatic carcinoma

Goldstein¹,

Carroll

Apte

et al. 2004

Internal Medicine Journal

View full text Add to dashboard Cite

Pancreatic cancer remains a fearsome disease. New insights into the molecular pathogenesis may influence choice of treatment modalities and provide avenues for novel therapeutic strategies for testing in the clinic. The survival rate of patients with all stages of disease is poor and clinical trials are appropriate alternatives for treatment and should be considered. Surgical resection, when possible, remains the primary treatment modality and can result in long-term cure. Less invasive techniques such as laparoscopy may reduce the rate of unnecessary laparotomies. The role of adjuvant therapy is re-emerging. Patients with unresectable and metastatic disease are incurable and optimal palliation is the goal. These patients may benefit from palliative bypass of biliary or duodenal obstruction if symptomatic. Pain associated with local tumour infiltration may be palliated with radiation, with or without chemotherapy, or with coeliac nerve blocks or local neurosurgical procedures. Chemotherapy with gemcitabine has modest objective response rates but has been shown to improve symptoms. (Intern Med J 2004; 34: 475-481)

show abstract

Section: Metastatic Diseasementioning

confidence: 70%

Section: Metastatic Diseasementioning

confidence: 99%